Are Peptides Legal? What the Rules Actually Say

"Are peptides legal" is one of the most-searched questions in this market and one of the least answerable as written, because it assumes a category that does not exist in the law. There is no statute about peptides. There are statutes about drugs, and where a given vial sits depends on what the product is and what it is intended for.

This page sets out what the rules say, quoted from the regulations and from FDA's own published records, with the dates they were read. It is journalism about a regulatory record, not legal advice. It does not tell anyone what they may lawfully do, it cannot account for state law or for any jurisdiction outside the United States, and the position of any specific product, seller or transaction is a question for a lawyer.

The question the law actually asks

United States drug law does not classify by molecule. It classifies by what a product is and what it is intended to be used for — and intended use is not established by a disclaimer. It is inferred from the whole of what a seller publishes.

That single principle explains most of what follows. It is why insulin and semaglutide are peptides and are approved medicines; why the same compound can be an approved drug in one context and an unapproved new drug in another; and why two sellers shipping chemically identical vials can be in very different positions depending on nothing more than the words on their product pages.

"Research use only" is a shipping rule, not a disclaimer

This is the part almost every page on this subject gets wrong, and it is checkable in one document.

The phrase comes from 21 CFR 312.160, headed "Drugs for investigational use in laboratory research animals or in vitro tests." It is not a liability waiver a seller chose to print. It is a regulation that authorises a specific kind of shipment, and it sets four conditions. The label is one of them.

One — the exact caution wording. A person may ship a drug "intended solely for tests in vitro or in animals used only for laboratory research purposes" if it is labelled:

CAUTION: Contains a new drug for investigational use only in laboratory research animals, or for tests in vitro. Not for use in humans.

Two — diligence about who is receiving it. The shipper "shall use due diligence to assure that the consignee is regularly engaged in conducting such tests and that the shipment of the new drug will actually be used for tests in vitro or in animals used only for laboratory research."

This is the condition that does the real work, and it is the one never mentioned in the market. The regulation does not contemplate an open storefront. It contemplates a shipper who has satisfied itself that the recipient is a laboratory that runs these tests as a matter of course. The duty to check sits with the seller.

Three — records naming the recipient. The shipper "shall maintain adequate records showing the name and post office address of the expert to whom the drug is shipped and the date, quantity, and batch or code mark of each shipment and delivery," kept for two years, and must let an authorised FDA officer "have access to and copy and verify" them on request.

The regulation calls the recipient the expert. It expects a named individual whose identity and address are on file and producible to a federal inspector.

Four — return of what is not used. The shipper "shall assure the return of all unused supplies of the drug from individual investigators whenever the investigation discontinues or is terminated." Alternative disposal is permitted only in writing and only where it "does not expose humans to risks from the drug, either directly or indirectly."

And the authorisation is revocable. Under 312.160(b), FDA may terminate it where the sponsor has failed to comply with any condition, or where "the continuance of the investigation is unsafe or otherwise contrary to the public interest or the drug is used for purposes other than bona fide scientific investigation."

Read together, the four conditions describe a supply channel between a manufacturer and a working laboratory. Whether any particular seller operates inside it is a question of fact about that seller, and not one this page decides. What the page can say is that the printed sentence is the first condition of four, and that the other three are about conduct rather than typography.

What FDA has said about named peptides — and the distinction everyone gets wrong

FDA maintains a page listing bulk drug substances used in compounding that may present significant safety risks. It is the document most often cited as proof that a given peptide has been "banned", and it is regularly misread, because it contains two different lists.

Read on 2026-09-07; the page states it is current as of 22 April 2026.

The formal category 2 table — substances FDA has identified as presenting significant safety risks in compounding — contains five peptide-class entries:

A separate section, headed "Bulk drug substances nominated but withdrawn", is where the compounds this market talks about most actually sit — BPC-157, thymosin beta-4 fragment (TB-500), CJC-1295, AOD-9604, melanotan II, epitalon, selank acetate, semax, thymosin-alpha-1 and cathelicidin LL-37. Their nominations were withdrawn; FDA kept its evaluation notes on the page.

The difference matters in both directions, and both errors are common. Saying "FDA put BPC-157 in category 2" overstates the record. Saying "FDA withdrew it, so the agency has no concerns" understates it, because the note was retained. What FDA actually wrote about BPC-157 is narrower and more interesting than either:

Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.

That is a statement about absent evidence, not about demonstrated harm. It is neither the endorsement nor the prohibition it gets quoted as.

Two entries in the same section are worth separating out, because they are the exception. For CJC-1295, FDA states it "has identified serious adverse events associated with CJC-1295 including increased heart rate" — an identified signal rather than an information gap. And in the category 2 table, ibutamoren mesylate is there because of a specific trial outcome: FDA records a randomised, placebo-controlled trial in patients recovering from hip fracture that "was terminated early due to a potential safety signal of congestive heart failure." Where a real signal exists, the agency says so plainly, which is what makes the absence of such language elsewhere on the page meaningful.

Note also what these classifications are. Category 2 is a compounding classification: it governs what a pharmacy or outsourcing facility may compound from bulk substance. It is not a controlled-substance schedule, and it is not a criminal prohibition on the molecule.

What enforcement has actually looked like

FDA's practical answer to this market has been warning letters, and they are the clearest available record of how the agency reasons. In every letter that addressed the phrase, FDA's position was that "research use only" labelling did not settle the intended-use question, and the evidence it cited was never the vial — it was the copy around the vial: therapeutic claims, dosing guides and calculators, bacteriostatic water offered alongside, and the seller's social channels.

Our tracker of those letters follows the record letter by letter and re-checks it monthly, including which have gone unanswered. It also documents something structural: FDA publishes no machine-readable version of this record at all, which is the mechanical reason so little of it reaches the summaries people actually read.

Sport is a separate system, answering a different question

Anti-doping rules are frequently folded into this question and should not be. They are contractual, not criminal: they bind people who accepted them by entering tested competition, and they are enforced by sporting bodies rather than by governments.

The consequence is that the two analyses can point opposite ways. A substance may be entirely lawful to possess and still end a career; growth hormone secretagogues, the GHRPs and a number of other peptides are prohibited at all times, in and out of competition, regardless of what any national law says about them. Neither analysis substitutes for the other, and a page that answers one while appearing to answer both is doing a disservice.

The limits of this page, stated plainly

This is a regulatory explainer written from primary documents. It is not legal advice and does not establish what any person may lawfully do.

Three limits in particular. It covers United States federal rules only — state law varies and is not treated here, and no other country's regime is. It describes where obligations sit in the text of regulations, which is not the same as predicting how any particular set of facts would be treated. And regulatory records move: the FDA compounding page carries its own "current as of" date, nominations are added and withdrawn, and guidance is issued and rescinded. Every date on this page is printed so that a reader can check whether it still holds.

Anyone with an actual decision to make — as a buyer, a seller, a clinician or a researcher — needs a lawyer who can see the specific facts. What this page offers is the documents that conversation should start from.

Sources and dates

21 CFR 312.160, read from the eCFR on 2026-09-07, quotations verbatim. FDA, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks," read 2026-09-07; the page states it is current as of 22 April 2026, and both the category 2 table and the "nominated but withdrawn" section were read from it in the same session. Warning-letter material is sourced and dated on our warning-letter tracker, which carries the individual letters and their dates.